Novogen Limited (NASDAQ:KZIA) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Novogen Limited (NASDAQ:KZIA) have been given an average recommendation of “Moderate Buy” by the five research firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $23.75.

A number of analysts recently weighed in on KZIA shares. Wall Street Zen lowered shares of Novogen from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. Laidlaw started coverage on Novogen in a research note on Wednesday, April 15th. They issued a “buy” rating and a $25.00 price target on the stock. Lake Street Capital started coverage on shares of Novogen in a report on Thursday. They issued a “buy” rating and a $32.00 target price for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Novogen in a research note on Tuesday, April 21st.

Novogen Stock Performance

KZIA stock traded up $0.48 during midday trading on Thursday, hitting $11.98. The company’s stock had a trading volume of 51,300 shares, compared to its average volume of 217,795. Novogen has a 52-week low of $4.86 and a 52-week high of $17.40. The firm has a 50-day simple moving average of $11.49 and a 200-day simple moving average of $9.23.

Novogen (NASDAQ:KZIA) last released its earnings results on Saturday, February 14th. The company reported ($1.34) EPS for the quarter. The company had revenue of $4.89 million during the quarter. On average, research analysts predict that Novogen will post -0.01 EPS for the current fiscal year.

About Novogen

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.